Ишнинг мацсади - Кушинг синдромини эрта аниқлаш учун Узбекистон Республикаси Наманган, Кашкадарё ва Хоразм вилоятларида юқори хавф гурухдарида скрининг натижаларини урганиш. Узбекистон Республикаси худудлари - Хоразм, Наманган ва Кашкадарё вилоятлари доирасида Амалий лойихд орқали 21990 шахслар мавзу учун скрининг цилигандан сунг 2195 шахслар синовлар учун танлаб олинди. 2185 одамлар уртасида эркаклар 639 нафар (29,2%) аёллар эса 1546 нафар (70,7%) булган. Хоразм, Наманган ва Кашкадарё вилоятларида юқори хавф гурухдарида асосан 1 даража семизлик аникданди (26,0%). Кортизолни сулакда аниклашда текширилувчиларда куйидаги узгаришлар аникданди: 385 беморларда (17,6%) кортизол сулакда (Хоразм ва Кдшкддарё вилоятлари), 198 (9%) беморларда сийдикда (Наманган вилояти) юқори булган. Жами 583 шахсларда кортизол сулак/ сийдикда ошгани аникданди (26,6%). Улар орасида 36-45 ёшдаги тана вазн индекси (ТВИ) юқори ва уртача даражадаги 175 та беморларда сулакдаги кортизол билан сезиларли фарқ борлиги аникланди. Кушинг синдроми скринингида сулак/ сийдикда кортизолни аникдаш юқори хавф гурухдари уртасида яхши индикатор вазифасини утайди.
The aim of study was to reseach the results of screening at risk groups of early detection of Cushing syndrome in Namangan, Kaskadarya and Khorezm regions of Uzbekistan. In total at the pilot regions of the Republic of Uzbekistan: Khorezm, Namangan and Kashkadarya regions 21,990 persons were undergone to CS screening and they were included in the applied project, of which 2,185 people were selected for further examination. From 2,185 patients men were 639 (29.2%), women were 1546 (70.7%). In the risk groups of patients were from Khorezm, Namangan and Kashkadarya regions, in the predominant majority, ldegree of obesity was (26.0%). The determination of cortisol in saliva revealed the following changes in our patients: 385 patients’ (17.6%) the saliva cortisol was higher than normal (Khorezm and Kashkadarya regions), and in urine it was in 198 (9%) patients (Namangan region). In total 583 people showed the increase cortisol in saliva / urine. (26.6%). Of these, the significant difference was found at control between BMI and elevated mean of salivary cortisol at 175 patients aged from 36 to 45 years. The determination of cortisol in saliva / urine were the qualitative indices at screening of Cushing’s syndrome in risk groups.
| № | Муаллифнинг исми | Лавозими | Ташкилот номи |
|---|---|---|---|
| 1 | Narimova G.D. | РСНПМЦ эндокринологии им акад. Ё.Х. Туракулова |
| № | Ҳавола номи |
|---|---|
| 1 | 1. Штифте А.К., Галвинош Г.А., Круминя Г.А. О результатах лечения синдрома и болезни Иценко-Ку- шинга // Вопросы эндокринологии. // Тез.доклад. -Тарту, 1984.-С. 208-209. 2. Ambrogio AG12, Cavagnini F3/./Role of "old” pharmacological agents in the treatment of Cushing’s syndrome. //J Endocrinol Invest.2016 Sep;39(9):957-65. doi: 10.1007/s40618-016-0462-4. Epub 2016 Apr 16. 3. Badia X1, Roset M, Valassi E. et all/Mapping CushingQOL scores to EQ-5D utility values using data from the European Registry on Cushing’s syndrome (ERCUSYN). //Qual Life Res. 2013 Dec;22(10):2941-50. doi: 10.1007/S11136-013-0396-7. Epub 2013 Mar 29. 4. Bertagna X1./Therapeutic innovations in endocrine diseases - Part 1: New medical treatments for chronic excess of endogenous cortisol (Cushing’s syndrome). //Presse Med. 2016 Jun;45(6 Pt2):e201-4. doi: 10.1016/j. lpm.2016.05.006. Epub 2016 May 27. 5. Broder MS, Chang E, Cherepanov D. et all/Identification Of Potential Markers For Cushing Disease. // EndocrPract. 2016 May;22(5):567-74. doi: 10.4158/EP15914.0R. Epub 2016 Jan 20. 6. Ceccato F1, Barbot M1, Zilio M' et all/Screening Tests for Cushing’s Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. // J ClinEndocrinolMetab.2015 0ct;100(10):3856-61. doi: 10.1210/jc.2015-2507. Epub 2015 Aug 14. 7. Ceccato F1, Barbot M1, Zilio M1. etall/ Screening Tests for Cushing’s Syndrome: Urinary Free Cortisol Role Measured by LC-MS/MS. //J ClinEndocrinolMetab.2015 0ct;100(10):3856-61. doi: 10.1210/jc.2015-2507. Epub 2015 Aug 14. 8. Eckstein N1, Haas B, Hass MD,. /Systemic therapy of Cushing’s syndrome.//Orphanet J Rare Dis. 2014 Aug 5;9:122. doi: 10.1186/sl3023-014-0122-8. 9. Holst JM1, Horv6th-Puhy E. et all/ Cushing"s syndrome in children and adolescents: a Danish nationwide population-based cohort study. //Eur J Endocrinol. 2017 May;176(5):567-574. doi: 10.1530/EJE-16-0843. Epub22017 Feb 8. 10. Llahana S12, Thomas N3./Structured nursing educational programs improve quality of life outcomes in patients with Cushing’s syndrome. //Endocrine. 2016 Jul;53(l):l-3. doi: 10.1007/sl2020-016-0934-5. Epub 2016 Apr 5. 11. Putignano P1, Bertolini M, Losa M.et all/Screening for Cushing’s syndrome in obese women with and without polycystic ovary syndrome //J Endocrinol Invest. 2003 Jun;26(6):539-44. 12. Tritos NA, Biller BM, Swearingen B. /Management of Cushing's syndrome. // Nat Rev Endocrinol. 2011;7:279-289 13. Valassi E1, Crespo I, Gich I. et all/A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. //ClinEndocrinol (0xf).2012 Nov;77(5):735-42.doi: 10.1111/j. 1365-2265.2012.04424.x. 14. Valassi E1, Franz H2, Brue T3 et all/ Diagnostic tests for Cushing’s syndrome differ from published guidelines: data from ERCUSYN. //Eur J Endocrinol.2017 May;176(5):613-624. doi: 10.1530/EJE-16-0967. Наримова Г.Д. |